Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Reply to: Caution at psychiatry’s psychedelic frontier and Challenges with benchmarking of MDMA-assisted psychotherapy

The Original Article was published on 11 October 2021

The Original Article was published on 11 October 2021

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. https://doi.org/10.1038/s41591-021-01336-3 (2021).

  2. Halvorsen, J. Ø. et. al. Nat. Med. doi (2021).

  3. Burke, M. J. et. al. Nat. Med. doi (2021).

  4. Feduccia, A. A. et al. Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front. Psychiatry September 2019, 1–7 (2019).

    Google Scholar 

  5. Jerome, L. et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacol. 237, 2485–2497 (2020).

    Article  CAS  Google Scholar 

  6. American Psychological Association. Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults 1st edn (APA, 2017).

Download references

Author information

Authors and Affiliations

Authors

Contributions

J. M., A. C. and B. Y.-K. contributed to the writing of this manuscript.

Corresponding author

Correspondence to Jennifer Mitchell.

Ethics declarations

Competing interests

A. C. and B. Y.-K. received salary support for full-time employment with MAPS PBC/MAPS, the trial organizer and sponsor.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mitchell, J., Coker, A. & Yazar-Klosinski, B. Reply to: Caution at psychiatry’s psychedelic frontier and Challenges with benchmarking of MDMA-assisted psychotherapy. Nat Med 27, 1691–1692 (2021). https://doi.org/10.1038/s41591-021-01526-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01526-z

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing